Huahui, BeOne strike $2.02B HH160 oncology option deal

Huahui Health has signed a global exclusive option, license, and collaboration agreement with BeOne Medicines for HH160, a preclinical trispecific antibody that targets PD-1, CTLA-4, and VEGF-A. Under the deal, BeOne will pay Huahui $20 million upfront, with another $100 million due if it exercises its option, and Huahui could receive up to $1.9 billion in development, regulatory, and sales milestones, plus tiered royalties. The companies said BeOne would gain worldwide rights to develop, manufacture, and commercialize HH160 if the option is exercised. HH160’s preclinical data were previously presented at the 2025 AACR annual meeting, and Huahui has described the candidate as part of its PolyBoost multispecific antibody platform. (biospace.com)

Why it matters: For veterinary professionals, this isn’t an animal health deal, but it’s still relevant as a signal of where immuno-oncology innovation and capital are moving. Multispecific antibody formats designed to combine checkpoint blockade and anti-angiogenic activity into a single molecule are drawing continued interest in human oncology, and those platform advances can shape how comparative oncology researchers, translational medicine teams, and industry watchers think about future cancer drug design across species. It also underscores that large biopharma companies are still willing to place sizable bets on preclinical assets when the biology and platform story look compelling. (biospace.com)

What to watch: The next key milestone is whether BeOne exercises its option and whether HH160 moves into first-in-human development on a timeline the companies are willing to disclose. (biospace.com)